It was a true honour to be part of this practice changing study #inmind for RR FL. Main messages in addition to better efficacy…fixed duration w/o excess events after tx stop, no added toxicity, excellent TTNT…works in high risk pts, my best choice for 2L FL. #lymsm#ash24
#ASH24 session acknowledging the legacy of Prof. Éliane Gluckman awarded the Wallace H. Coulter award for a lifetime of achievement in cord blood transplantation.
Room packed with attendees and excitement in anticipation of the Plenary Session!
#womeninmedicine
Teaching at #ESMOAcademy, @myESMO in Zurich about #Hodgkin. Great audience.
My take home:
📣 PET CT at dx and after 2 chemo decide treatment
📣 Limit relapse check-up to 2 years, next focus on late effects
📣 Fertility counseling
📣 BrECADD new standard
📣 Nivo-AVD in elderly?
O can safely be used in combination with chemotherapy and in maintenance after ASCT as frontline therapy in patients with MCL. https://t.co/tndKk0gxUr #clinicatrialsandobservations#lymphoidneoplasia
Ce 12 juillet, les pilotes de la @PAFofficiel ont laissé leurs alphajets pour venir visiter @HopSaintLouis par le biais de l’association @AssoELLyE.
Un elan du cœur pour les patients atteints de lymphome et ceux qui les soignent 🇫🇷❤️
Cc @APHP@c_thieblemont@FenauxP
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma | Journal of Clinical Oncology https://t.co/NF1tM1EL6r
📢 Proud to see this important, timely comment by @DrLauraEsserman & @DougYeeMD just published in @NatureMedicine. I 💯 agree: Science & medical groups should stop holding conferences in anti-choice states. Abortion IS healthcare! #WomensRights
Please RT!
https://t.co/88lqXYsDPv
DESCAR-T strikes again…
Largest study on transfusion use post CART led by @HouotRoch out today in @BloodAdvances ⤵️
https://t.co/KhHkntn1Mp
Enjoyed writing the associated commentary with @moh7madhomod! Check it out ⤵️
https://t.co/qxgMb1u5VR
@MSKCancerCenter
Final Analysis of the Ro-CHOP Trial in T-cell lymphoma: In an exploratory analysis, the median PFS in the centrally reviewed follicular helper T-cell lymphoma subgroup was significantly longer in the Ro-CHOP arm. @JCO_ASCO https://t.co/PHrlYophq3
Célébrez Noël 🎅🏼 en offrant les meilleurs équipements d’activité physique adaptée pour les patients atteints de lymphome!
Car oui, la forme physique optimise les résultats thérapeutiques.💪
Un grand merci pour votre générosité. 🎄🎁
Cc @c_thieblemont@Roberta04704608@APHP
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study https://t.co/ydQfPLoNf8
It was such an exciting time presenting our data on SYMPATICO trial. It is a milestone achievement for our patients with mantle cell lymphoma in the world!
Finally, analyzing 310 blood samples from 109 patients we found that #PhasEDSeq#MRD better captures relapse risk than functional imaging by PETCT. 12/15
Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma#cHL out today @Nature. #lymsm 1/15
https://t.co/FOBvWSu5Je PDF link at bottom of this thread